Vertex: More Appealing At A Lower Price, But Don't Rush In (Rating Upgrade)
Vertex Software faces strong competition and slower growth, leading to a neutral rating. See why VERX stock remains pricey ...
Vertex Discontinues Development Of Type 1 Diabetes Candidate After Disappointing Data
Vertex halts VX-264 trials after missing efficacy goals but continues advancing zimislecel, a potential treatment for severe ...
Fierce Biotech4d
Vertex abandons islet cell-device combo after failing to improve diabetes biomarker
Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to ...
BioSpace4d
Vertex Cuts Diabetes Asset, but Analysts Keen on Phase III Option
Despite a $400 million impairment charge, analysts say the removal of a drug-device combo from its portfolio is not a huge ...
Vertex non-opioid painkiller Journavx gets mixed ICER review
ICER's evaluation of Vertex Pharmaceuticals' non-opioid pain drug, Journavx, finds cost-effectiveness related to potential ...
Pharmaceutical Technology on MSN4d
Vertex halts development of diabetes cell therapy after trial failure
Vertex continues to develop type 1 diabetes therapy, zimislecel, which is being investigated in a Phase III trial.
pharmaphorum6d
Vertex buys diabetes cell therapy rival ViaCyte for $320m
Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...